END TO END PREPAREDNESS FOR PANDEMIC INFLUENZA

[AlaskaDenise]

interesting conference. No big names, but check the agencies/companies...

http://www.infocastinc.com/pand06/agenda.html
"Opportunities for Public-Private collaboration"

AGENDA

END TO END PREPAREDNESS FOR PANDEMIC INFLUENZA
Tuesday November 14 - Wednesday, November 15, 2006

Hear from these currently confirmed speakers:
Keynote Speaker:
The Honorable Mike Rogers, Congressman (R-MI)
Featured Speakers:
Anne Schuchat, M.D.,Rear Admiral, United States Public Health Service; Assistant Surgeon General; Director, National Center for Immunization and Respiratory Diseases (proposed), Centers For Disease Control And Prevention (CDC)
Franz Kracher, Ph.D., Project Officer, Unit SANCO C3 ? Health Threats, DG Health and Consumer Protection, Director C Public Health and Risk Assessment, European Commission
James Young, Ph.D., President, Research & Development, MedImmune, Inc.



And Senior Representatives from:
Government Agencies
Steven A. Adams, MPH, Director (acting), Division of Strategic National Stockpile (SNS) , Centers for Disease Control and Prevention (CDC)
Erik A. Henchal, Ph.D., FAAMM, Associate Director, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)
Robin Robinson Ph.D., Acting Associate Director for Influenza Programs, Office of Research and Development Coordination, Office of Public Health Emergency Preparedness, Department Of Health & Human Services (DHHS)
Biopharmaceutical Companies
Kim C. Bush, President, Baxter Vaccines
James Matthews, Ph.D., Senior Director, Health and Science Policy, Sanofi Pasteur SA
Mike McGuire, Vice President, Anti-Infectives Marketing, Roche
Garry Redlich, Managing Director, Implicit Bioscience Pty Ltd.
Sarah R. Landry, Director of Public Policy-Vaccines, GlaxoSmithKline.
Hal Siegel, Ph.D. Senior Director of Development and Regulatory Affairs, ImmuneRegen BioSciences, Inc.
Rahul Singhvi, Ph.D., President and CEO, Novavax Inc.
Friso van Voorthuizen, Ph.D., Global Director Pandemic Preparedness & Manufacturing Liaison, Solvay Pharmaceuticals B.V.
Medicine and Supply Distributors
Claude Grant, Senior Vice President, Quality and Regulatory Affair, Cardinal Health
Chris Ground, Senior Vice President, National Accounts, FFF Enterprises, Inc.
Neil Herson, President, ASD Healthcare
Others Key Advisors:
Bill Helming, Vice President, Biodefense and Public Health Practice, PRTM Management Consultants
John A. Muckstadt, Acheson/Laibe Professor of Business Management and Leadership Studies, School of Operations Research and Industrial Engineering, Cornell University
Frank M. Rapoport, Partner, McKenna Long & Aldridge LLP
Sharon Seiler, Ph.D., Vice President ? Senior Biotechnology Analyst, Punk, Ziegel & Company
​

 

[AlaskaDenise]

Re: END TO END PREPAREDNESS FOR PANDEMIC INFLUENZA

the Symposium Agenda....

Supply Chain Readiness for Pandemic Influenza Response

Monday, November 13, 2006​

The readiness of the national medical supply chain to handle the daunting task of managing the flow and administration of medicines and supplies during a pandemic is of paramount national concern. This Symposium will bring together leading experts from government, industry, and public health entities to address how the supply chain for vaccines, therapeutics, and medical supplies will actually be managed during a pandemic. Through presentations and interactive discussions, speakers representing three major components of the pandemic response supply chain-production, supply, and administration-will focus on the integration and coordination of key components in the supply chain, highlight any gaps that may exist, and explore strategies for addressing those gaps.
.​